In medical news:

The FDA has issued its long-awaited finalized guidance for industry on the development of abuse-deterrent opioids. The guidance has been a work in progress since an initial draft was released over two years ago (January 2013) and addresses the types of studies needed to establish abuse-deterrence and how those studies should be performed and evaluated. Additionally, the guidance delineates the acceptable labeling claims for abuse-deterrent drugs after the required studies have been performed. There will be four labels corresponding to different categories. Category placement depends upon the level of evidence for each opioid’s abuse-deterrent properties. Importantly, the guidance does not mandate that all new opioids must be abuse deterrent.

Read more from MedPage Today here. Read the guidance from the FDA in full here.

Leave a Comment

Your email address will not be published. Required fields are marked *